Effect of compression force on the crystal properties of erythromycin acistrate tablets.
The crystal properties of compressed and powdered erythromycin acistrate tablets were studied by the X-ray powder diffraction (XRPD) method. Detailed analysis of X-ray powder diffraction line profiles was performed. Diffraction peak intensities and full width at half maximum (FWHM) values of the peaks corresponding to three different crystal lattice directions were determined. Crystallite size was calculated by Scherrer's equation using the data of integral breadth of the peaks. The preferred orientation of the crystallites is also discussed. According to the results, the crystallite size increased on the tablet surface after a small compression force (4 kN) in all crystal lattice directions studied. Even small compression forces caused recrystallization. With higher compression forces (8-18 kN) the crystallite size and the FWHM values remained rather constant. After the compression force of 18 kN the peaks in different crystal lattice directions behaved differently. In the lattice directions of diffraction maxima 2 and 3, the effect was the same with the small (4 kN) and the high compression force (22 kN). Further recrystallization occurred with 22 kN. However, in the crystal lattice direction of diffraction maximum 1 at the compression force of 8 kN the crystallite broke and crystallinity decreased. These were not seen in the powdered tablet samples. It could be concluded that the effect of compression force on the crystal properties of erythromycin acistrate tablets was seen on the tablet surface but not in the powdered tablets. Compression force also affected the preferred orientation of crystallites on the tablet surface and especially in the lattice direction of diffraction maximum 3. This was not seen in the powdered tablets.
Riippi
M
M
R & D, Orion Corporation, Orion Pharma, Espoo, Finland. merja.riipi@orion.fi
Tanninen
V
V
Yliruusi
J
J
D002626:Chemistry, Pharmaceutical; D019245:Compressive Strength; D003460:Crystallization; D004917:Erythromycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D011208:Powders; D011355:Prodrugs / Q000008:administration & dosage / Q000737:chemistry*; D013607:Tablets; D014961:X-Ray Diffraction
D011208:Powders; D011355:Prodrugs; D013607:Tablets; D004917:Erythromycin; C056625:erythromycin 2'-acetate